Clinical trials
Completed Neuroma, Acoustic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| NYU Langone Health | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| National Cancer Institute (NCI) | 2 |
| University Hospital Tuebingen | 2 |
| Assistance Publique Hopitaux De Marseille | 1 |
| Beijing Tiantan Hospital | 1 |
| Charles University, Czech Republic | 1 |
| Emory University | 1 |
| FDA Office of Orphan Products Development | 1 |
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuroma, Acoustic | 37 |
| Neurofibromatosis 2 | 12 |
| Meningioma | 5 |
| Brain Neoplasms | 4 |
| Ependymoma | 3 |
| Glioma | 3 |
| Neurilemmoma | 3 |
| Astrocytoma | 2 |
| Central Nervous System Neoplasms | 2 |
| Craniopharyngioma | 2 |
Trials
Showing 76 to 37 of 37. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.